JP2018530349A - ヒストンｈ３−リシントリメチル化の排除によりヒト体細胞核移入（ｓｃｎｔ）の効率を増加する方法および組成物、ならびにヒトｎｔ−ｅｓｃの誘導方法 - Google Patents

ヒストンｈ３−リシントリメチル化の排除によりヒト体細胞核移入（ｓｃｎｔ）の効率を増加する方法および組成物、ならびにヒトｎｔ−ｅｓｃの誘導方法 Download PDF

Info

Publication number
JP2018530349A
JP2018530349A JP2018538060A JP2018538060A JP2018530349A JP 2018530349 A JP2018530349 A JP 2018530349A JP 2018538060 A JP2018538060 A JP 2018538060A JP 2018538060 A JP2018538060 A JP 2018538060A JP 2018530349 A JP2018530349 A JP 2018530349A
Authority
JP
Japan
Prior art keywords
human
scnt
oocyte
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018538060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530349A5 (enExample
Inventor
イ チャン
イ チャン
ドン リュル リー
ドン リュル リー
章悟 的場
章悟 的場
ユン ジエ チャン
ユン ジエ チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2018530349A publication Critical patent/JP2018530349A/ja
Publication of JP2018530349A5 publication Critical patent/JP2018530349A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8776—Primate embryos
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11027—[Histone H3]-lysine-36 demethylase (1.14.11.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018538060A 2015-10-09 2016-10-07 ヒストンｈ３−リシントリメチル化の排除によりヒト体細胞核移入（ｓｃｎｔ）の効率を増加する方法および組成物、ならびにヒトｎｔ−ｅｓｃの誘導方法 Pending JP2018530349A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562239318P 2015-10-09 2015-10-09
US62/239,318 2015-10-09
US201562242050P 2015-10-15 2015-10-15
US62/242,050 2015-10-15
PCT/US2016/055890 WO2017062706A1 (en) 2015-10-09 2016-10-07 Methods and compositions to increase human somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation, and derivation of human nt-esc

Publications (2)

Publication Number Publication Date
JP2018530349A true JP2018530349A (ja) 2018-10-18
JP2018530349A5 JP2018530349A5 (enExample) 2019-11-14

Family

ID=58488507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018538060A Pending JP2018530349A (ja) 2015-10-09 2016-10-07 ヒストンｈ３−リシントリメチル化の排除によりヒト体細胞核移入（ｓｃｎｔ）の効率を増加する方法および組成物、ならびにヒトｎｔ−ｅｓｃの誘導方法

Country Status (6)

Country Link
US (3) US20180291400A1 (enExample)
EP (1) EP3359167A4 (enExample)
JP (1) JP2018530349A (enExample)
KR (1) KR20210143952A (enExample)
CN (1) CN109641015A (enExample)
WO (1) WO2017062706A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102473092B1 (ko) 2014-09-15 2022-12-01 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
CN107299113A (zh) * 2017-06-12 2017-10-27 内蒙古大学 H3K27me3及其去甲基化酶KDM6A/B在小鼠核移植重构胚中的应用方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN111630176A (zh) * 2018-01-23 2020-09-04 车医科学大学校产学协力团 一种包括Rad51激活剂的用于胚胎发育的组合物以及用其提高胚胎发育率的方法
WO2019147026A1 (ko) * 2018-01-23 2019-08-01 차의과학대학교 산학협력단 멜라토닌을 포함하는, 배아 발달용 조성물 및 이를 이용하여 배아 발달의 효율을 향상시키는 방법
WO2019195738A1 (en) * 2018-04-06 2019-10-10 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
EP3823663A4 (en) * 2018-07-19 2022-03-09 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR GENERATING A PHYSIOLOGICAL X-CHROMOSOME INACTIVATION
EP4386081A3 (en) * 2019-05-21 2024-10-16 President and Fellows of Harvard College Endocrine differentiation-inducing molecule
CN110607325B (zh) * 2019-09-19 2021-03-23 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 一种提高修正的人三原核受精卵体外培养囊胚发育率的方法
CN116113421A (zh) 2020-05-14 2023-05-12 阿莱兹精准医疗公司 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗
US20240350492A1 (en) * 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss
US20230372311A1 (en) * 2020-07-21 2023-11-23 The Regents Of The University Of California Compositions and methods of treating age-related retinal dysfunction
CN112382339B (zh) * 2020-11-17 2024-08-13 中国人民解放军军事科学院军事医学研究院 一种识别合子型基因激活zga基因的方法及装置
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
CN113186152B (zh) * 2021-05-19 2023-05-26 南方医科大学 Dna甲基转移酶抑制剂在提高动物圆形精子注射胚胎发育效率中的应用
CN115247175B (zh) * 2021-11-25 2025-10-17 南京启真基因工程有限公司 构建setdb1基因突变的表观遗传失调模型猪核移植供体细胞的基因编辑系统及其应用
WO2025042589A1 (en) * 2023-08-18 2025-02-27 University Of Washington Compositions and methods for improving cardiac regeneration
CN118956808B (zh) * 2024-10-17 2025-01-07 天津赛萌生物技术有限公司 一种setdb1突变体及其在生物大分子制备中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143421A2 (en) * 2008-05-22 2009-11-26 The Johns Hopkins University Methods for promoting fusion and reprogramming of somatic cells
WO2011082038A2 (en) * 2009-12-31 2011-07-07 Fate Therapeutics, Inc. Improved reprogramming compositions
WO2014125363A1 (en) * 2013-02-15 2014-08-21 Sung Kwang Medical Foundation Production of parthenogenetic stem cells and patient-specific human embryonic stem cells using somatic cell nuclear transfer
US20140335619A1 (en) * 2013-05-13 2014-11-13 Oregon Health & Science University Human pluripotent stem cells produced by somatic cell nuclear transfer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483817A (zh) * 2002-09-18 2004-03-24 李建远 一种克隆无动物成分的人胚胎干细胞的方法
CN101535468A (zh) * 2005-10-21 2009-09-16 国际干细胞公司 单性生殖激活人类卵母细胞用于产生人类胚胎干细胞
US20110172107A1 (en) * 2008-04-30 2011-07-14 Fox Chase Cancer Center Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
WO2014197835A2 (en) * 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143421A2 (en) * 2008-05-22 2009-11-26 The Johns Hopkins University Methods for promoting fusion and reprogramming of somatic cells
WO2011082038A2 (en) * 2009-12-31 2011-07-07 Fate Therapeutics, Inc. Improved reprogramming compositions
WO2014125363A1 (en) * 2013-02-15 2014-08-21 Sung Kwang Medical Foundation Production of parthenogenetic stem cells and patient-specific human embryonic stem cells using somatic cell nuclear transfer
US20140335619A1 (en) * 2013-05-13 2014-11-13 Oregon Health & Science University Human pluripotent stem cells produced by somatic cell nuclear transfer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL STEM CELL, 2014, VOL.14, PP.777-780, JPN6020044879, ISSN: 0004396264 *
CELL, 2014, VOL.159, PP.884-895, JPN6020044877, ISSN: 0004557296 *

Also Published As

Publication number Publication date
US20180298405A1 (en) 2018-10-18
EP3359167A4 (en) 2019-11-13
WO2017062706A1 (en) 2017-04-13
US20180291400A1 (en) 2018-10-11
KR20210143952A (ko) 2021-11-30
EP3359167A1 (en) 2018-08-15
US20200181648A1 (en) 2020-06-11
CN109641015A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
JP7277494B2 (ja) ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物
US20200181648A1 (en) Methods and compositions to increase human somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation, and derivation of human nt-esc
EP1979470B1 (en) Cell culture
EP3772928B1 (en) Compositions and methods for somatic cell reprogramming and modulating imprinting
JP2025533324A (ja) Ｃｒｉｓｐｒ ｖ型系の治療への応用
CN114207119A (zh) 用于细胞重编程的组合物和方法
US9163234B2 (en) Culture method
CN113316457A (zh) 用于生成生理性x染色体失活的组合物和方法
HK40007627A (en) Methods and compositions to increase human somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation, and derivation of human nt-esc
Ye et al. Jin K
JP2025532585A (ja) 組み合わせ遺伝子摂動を有する免疫細胞
CN118974253A (zh) Crispr v型系统的治疗应用
HK40047167A (en) Compositions and methods for somatic cell reprogramming and modulating imprinting
HK40047167B (en) Compositions and methods for somatic cell reprogramming and modulating imprinting
Oh Reprogramming Pluripotent Stem Cell Towards Totipotency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210728